---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-285236"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:53:34.368047+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q3 2022 revenue $6.9M, net loss $12.6M; completed spin-off from Ligand

## Summary
- Revenue $6.9M in Q3 2022 vs $6.3M in Q3 2021; net loss $12.6M vs $7.9M.
- Completed tax-free spin-off from Ligand and merger with Avista on Nov 1, 2022; net cash ~$96M.
- 68 active partners; 25 OmniAb-derived programs in clinic/commercial; 282 partner programs.
- Janssen received FDA and EU approval for TECVAYLI; OmniAb eligible for up to $35M in milestones.
- New platform deals with Dianthus, Hillstream, NGM Bio, TriPhase, Talem, and a stealth biotech.

## SEC filing metadata
- accession: 0001193125-22-285236
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/0001193125-22-285236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/d372979d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-285236
- JSON: https://secwatch.observer/filing/0001193125-22-285236.json
- Plain text: https://secwatch.observer/filing/0001193125-22-285236.txt

## Key facts
- Earnings Releases
  OmniAb, Inc. reported the nine months ended September 30, 2022 results: revenue $23.7 million, net income $29.2 million.
  - Period: the nine months ended September 30, 2022
  - Revenue: $23.7 million
  - Net income: $29.2 million
  - Result: reported results
  source text: Revenue for the nine months ended September 30, 2022 was $23.7 million, compared with $19.5 million for the same period in 2021, with the increase driven by higher milestone revenue, higher royalty revenue due to the launch of zimberelimab and sugemalimab in China and additional collaboration revenue. Research and development expense was $35.4 million for the nine months ended September 30, 2022, compared with $28.2 million for the same period of 2021, with the increase primarily due to continued investment in facilities and headcount. General and administrative expense was $14.7 million for the nine months ended September 30, 2022, compared with $12.6 million for the same period in 2021, with the increase primarily due to the spin-off and business combination, as well as headcount-related expenditures. Net loss for the nine months ended September 30, 2022 was $29.2 million, compared with net loss of $24.0 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/0001193125-22-285236-index.htm
- Earnings Releases
  OmniAb, Inc. reported the three months ended September 30, 2022 results: revenue $6.9 million, net income $12.6 million.
  - Period: the three months ended September 30, 2022
  - Revenue: $6.9 million
  - Net income: $12.6 million
  - Result: reported results
  source text: Revenue for the third quarter of 2022 was $6.9 million, compared with $6.3 million for the same period in 2021, with the increase primarily driven by higher royalty revenue due to the launch of zimberelimab and sugemalimab in China. Research and development expense was $13.2 million for the third quarter of 2022, compared with $9.9 million for the same period in 2021, with the increase primarily due to continued investment in facilities, headcount and technology innovation initiatives. General and administrative expense was $5.6 million for the third quarter of 2022, compared with $3.7 million for the same period in 2021, with the increase primarily due to headcount-related expenditures in preparation for becoming an independent publicly traded company. Net loss for the third quarter of 2022 was $12.6 million, compared with a net loss of $7.9 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000119312522285236/0001193125-22-285236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.